SAFETY ASSESSMENT CONSIDERATIONS FOR ANTIBODY DRUG CONJUGATES

被引：0
|
作者：
Hinkle, Beth [1 ]
机构：
[1] Amgen Inc, Thousand Oaks, CA USA
来源：
DRUG METABOLISM REVIEWS | 2012年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：23 / 24
页数：2
相关论文
共 50 条
  • [1] Antibody Drug Conjugates: Nonclinical Safety Considerations
    Mary Jane Masson Hinrichs
    Rakesh Dixit
    The AAPS Journal, 2015, 17 : 1055 - 1064
  • [2] Antibody Drug Conjugates: Nonclinical Safety Considerations
    Hinrichs, Mary Jane Masson
    Dixit, Rakesh
    AAPS JOURNAL, 2015, 17 (05): : 1055 - 1064
  • [3] Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology
    Roberts, Stanley A.
    Andrews, Paul A.
    Blanset, Diann
    Flagella, Kelly M.
    Gorovits, Boris
    Lynch, Carmel M.
    Martin, Pauline L.
    Kramer-Stickland, Kimberly
    Thibault, Stephane
    Warner, Garvin
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2013, 67 (03) : 382 - 391
  • [4] Antibody drug conjugates: Design considerations for improving efficacy and safety
    Trail, Pamela
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
  • [5] Considerations for the Nonclinical Safety Evaluation of Antibody-Drug Conjugates
    Fisher, J. Edward, Jr.
    ANTIBODIES, 2021, 10 (02)
  • [6] Practical Considerations for the Pharmacokinetic and Immunogenic Assessment of Antibody–Drug Conjugates
    Melody Sauerborn
    William van Dongen
    BioDrugs, 2014, 28 : 383 - 391
  • [7] Antibody Drug Conjugates: Preclinical Considerations
    Bornstein, Gadi G.
    AAPS JOURNAL, 2015, 17 (03): : 525 - 534
  • [8] Pharmacokinetic Considerations for Antibody Drug Conjugates
    Lin, Kedan
    Tibbitts, Jay
    PHARMACEUTICAL RESEARCH, 2012, 29 (09) : 2354 - 2366
  • [9] Pharmacokinetic Considerations for Antibody Drug Conjugates
    Kedan Lin
    Jay Tibbitts
    Pharmaceutical Research, 2012, 29 : 2354 - 2366
  • [10] Antibody Drug Conjugates: Preclinical Considerations
    Gadi G. Bornstein
    The AAPS Journal, 2015, 17 : 525 - 534
12345